Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erasca, Inc. stock logo
ERAS
Erasca
$1.31
+4.0%
$1.38
$1.01
$3.45
$371.11M1.091.70 million shs1.89 million shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$98.67
+2.4%
$109.02
$0.01
$155.12
$538.74M0.8851,106 shs479,511 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$3.83
-4.3%
$3.35
$1.87
$11.40
$334.51M-0.181.47 million shs1.46 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erasca, Inc. stock logo
ERAS
Erasca
0.00%-4.38%-7.42%-4.38%-44.49%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.00%+2.97%-3.91%-16.85%+13.71%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%-1.79%+22.76%+38.77%-43.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Erasca, Inc. stock logo
ERAS
Erasca
3.0047 of 5 stars
3.51.00.00.03.32.51.3
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
3.113 of 5 stars
3.03.00.80.02.22.51.3
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4.2091 of 5 stars
3.31.00.04.13.33.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Erasca, Inc. stock logo
ERAS
Erasca
3.00
Buy$4.57248.96% Upside
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.00
Hold$130.0031.75% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63307.96% Upside

Current Analyst Ratings Breakdown

Latest MLAB, ERAS, and TERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2025
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$120.00 ➝ $100.00
5/14/2025
Erasca, Inc. stock logo
ERAS
Erasca
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$3.00
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
4/30/2025
Erasca, Inc. stock logo
ERAS
Erasca
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
4/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.50 per shareN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$240.98M2.24$12.26 per share8.05$29.42 per share3.35
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Erasca, Inc. stock logo
ERAS
Erasca
-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
-$1.97M-$0.37N/A11.32N/A-0.82%27.51%9.78%8/4/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)

Latest MLAB, ERAS, and TERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Erasca, Inc. stock logo
ERAS
Erasca
-$0.12-$0.11+$0.01-$0.11N/AN/A
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$0.640.65%N/AN/A N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A

Latest MLAB, ERAS, and TERN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2025
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
quarterly$0.160.59%5/30/20255/30/20256/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Erasca, Inc. stock logo
ERAS
Erasca
N/A
12.35
12.35
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.48
0.63
0.47
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
30.89
30.89

Institutional Ownership

CompanyInstitutional Ownership
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
90.60%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Erasca, Inc. stock logo
ERAS
Erasca
14.40%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
4.40%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120283.29 million242.49 millionOptionable
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
6805.46 million5.22 millionNot Optionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million86.03 millionNot Optionable

Recent News About These Companies

Terns pharmaceuticals CEO Burroughs buys $90k in shares
3 Penny Stocks Wall Street Sees With 243% Upside

New MarketBeat Followers Over Time

Media Sentiment Over Time

Erasca stock logo

Erasca NASDAQ:ERAS

$1.31 +0.05 (+3.97%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.25 -0.06 (-4.58%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Mesa Laboratories stock logo

Mesa Laboratories NASDAQ:MLAB

$98.67 +2.31 (+2.40%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$0.01 -98.66 (-99.99%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$3.83 -0.17 (-4.25%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$4.38 +0.55 (+14.36%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.